Source: Eur Respir J 2014; 43: 322-324
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Oga Toru, Chin Kazuo, Mishima Michiaki. Towards the next stage of novel biomarker discussion in COPD: Tekizai-Tekisho. Eur Respir J 2014; 43: 322-324

Member's Comments

No comment yet.

Related content which might interest you: Discovery of novel disease-related biomarkers for GOLD stage II COPD: A prospective exploratory clinical study Source: Annual Congress 2010 - Novel mechanisms in COPD Year: 2010 Desmosine, a biomarker for COPD: old and in the way Source: Eur Respir J 2012; 39: 797-798 Year: 2012 A new paradigm for classification of disease severity and progression of COPD Source: Annual Congress 2012 - Prevalences and characterstics of obstructive airway disease Year: 2012 What is the best biomarker of COPD stability? Source: International Congress 2015 – COPD: chronic disease and comorbidities Year: 2015 Metabolomic signature in COPD. Plasma and lung tissue comparison identify sphingolipids as potential biomakers Source: International Congress 2014 – Markers Year: 2014 Mortality risk prediction in COPD by a prognostic biomarker panel – Results of a derivation and validation cohort with a long term follow-up Source: International Congress 2014 – Markers Year: 2014 Microalbuminuria as a potential novel cardiovascular biomarker in patients with COPD Source: Eur Respir J 2014; 43: 951-953 Year: 2014 COPD screening and risk factor frequency identification study Source: Annual Congress 2013 –Disease control and quality of life in airway diseases Year: 2013 COPD: implementing biomarkers to improve prognosis Source: Virtual Congress 2021 – Clinical year in review Year: 2021 The quest for biomarkers in asthma: challenging the T2 versus non-T2 paradigm Source: Eur Respir J, 59 (2) 2102669; 10.1183/13993003.02669-2021 Year: 2022 Application of omics technologies to the identification of biomarkers for COPD Source: Annual Congress 2007 - Cell biology of asthma and COPD Year: 2007 Z-alpha1-antitrypsin polymers and small airways disease: a new paradigm in COPD development? Source: Virtual Congress 2020 – Prediction of outcomes in obstructive diseases Year: 2020 Clinical phenotyping of COPD patients: a simple tool with prognosis value Source: International Congress 2018 – COPD phenotypes: a1 antitrypsin deficiency and beyond Year: 2018 Clustering asthma and COPD provides new evidence for both “British” and “Dutch” hypotheses of COPD development Source: Annual Congress 2013 –Risk factors for COPD and lung function decline Year: 2013 GOLD BCD or 234 classifications: Which one better reflects COPD patients' functionality? Source: International Congress 2014 – Physical activity, exercise and physiotherapy in patients with COPD Year: 2014 Wood smoke COPD: a new description of a COPD phenotype? Source: Eur Respir J 2014; 44: 262-263 Year: 2014 Wood smoke COPD: a new description of a COPD phenotype? Source: Eur Respir J 2014; 44: 261-262 Year: 2014 The challenge of getting the right diagnosis: asthma and COPD, new diagnostic possibilities Source: International Congress 2016 – Primary Care Day: challenging times I Year: 2016 Neutrophil-to-lymphocyte ratio in IPF patients: a novel prognostic biomarker? Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020 The concept of control in COPD: a new proposal for optimising therapy Source: Eur Respir J 2014; 44: 1072-1075 Year: 2014